Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Califf Sees Potential For New Emergency Use Authorities But Concerned About Industry Follow Through
Feb 20 2023
•
By
Sarah Karlin-Smith
Industry’s historic lack of follow through on post-market studies for expedited pathways could hinder the FDA's willingness to push the limits of the EUA pathway. • Source: Shutterstock
More from Review Pathways
More from Pathways & Standards